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Abstract
Sensitivity to immune checkpoint inhibitor (ICPI) therapy is governed by a complex interplay of tumor and host-
related determinants. Epidemiological studies have highlighted that exposure to antibiotic therapy influences the
probability of response to ICPI and predict for shorter patient survival across malignancies. Whilst a number of
studies have reproducibly documented the detrimental effect of broad-spectrum antibiotics, the immune-biologic
mechanisms underlying the association with outcome are poorly understood. Perturbation of the gut microbiota,
an increasingly well-characterized factor capable of influencing ICPI-mediated immune reconstitution, has been
indicated as a putative mechanism to explain the adverse effects attributed to antibiotic exposure in the context of
ICPI therapy. Prospective studies are required to validate antibiotic-mediated gut perturbations as a mechanism of
ICPI refractoriness and guide the development of strategies to overcome this barrier to an effective delivery of anti-
cancer immunotherapy.
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Introduction
Antibiotic therapy has produced unquestionable ad-
vances in the management of patients with cancer, a
population with intrinsically higher risk of bacterial in-
fection as a result of malignancy or treatment-related
immune suppression.
While antimicrobial therapy has markedly reduced
morbidity and mortality stemming from infection, the
effects of broad-spectrum antibiotics on commensal,
non-pathogenic bacterial species have remained for a
long time an under-appreciated effect of this therapeutic
class of drugs.
The gut microbiota, source of over 100 trillion bacteria,
exists in a condition of mutually beneficial relationship
with the host. Commensal bacteria are provided with a
niche to colonise the host in return for their participation
in the digestion of nutrients and xenobiotics, protection
from pathogens and shaping of the host’s immune system
subsets. Derangement of this delicate relationship has
been increasingly well-characterised in the context of
tumour-specific immune tolerogenesis [1].
Multiple levels of evidence now support the link between
sensitivity to immunotherapy, taxonomic diversity and en-
richment in specific gut bacterial taxa, suggesting that some
species or species consortia provide intrinsic immune-
modulating properties. The landmark study by Gopalakrish-
nan [2] demonstrated how broader stool bacterial diversity
and higher representation of Ruminococcaceae communities
including Faecalibacterium positively influences patients’ sur-
vival following ICPI by promoting a strongly immune-
reactive microenvironment and lower systemic release of
pro-inflammatory cytokines [3]. Many other commensal bac-
teria have subsequently been recognised to play a similar role
including Bifidobacteria spp., a saccarolytic Gram-positive
genus highly represented within the gut that facilitates den-
dritic cell maturation and increased accumulation of antigen-
specific T-cells within the tumour microenvironment [4].
Similarly, the presence of the anaerobic commensal Akker-
mansia Muciniphila is more common in responders to ICPI,
who display higher peripheral CD4 and CD8 memory T-cell
responses to this bacterium [5].
Antibiotic (ATB) therapy imposes profound and pro-
tracted changes to the taxonomic diversity of the host
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microbial ecosystem, affecting the composition of up to
30% of the bacterial species in the gut microbiome [6],
consequently leading to loss of microbial functions that
are protective for the host. Such changes in gut micro-
bial communities are rapid and pervasive, occurring
within days from the first antibiotic dose [7] and persist-
ing for up to several months after completion of therapy
[8].
Mounting evidence from epidemiological studies has
underscored the detrimental role of antibiotics in ICPI out-
come, with exposure to antibiotics having been linked to
shortened progression-free, overall survival and reduced re-
sponse rates in patients receiving ICPI as part of clinical trials
and in routine practice (Table 1). In a previous study, we
demonstrated time-dependence of antibiotics exposure as a
strong, tumour-agnostic determinant of outcome in ICPI re-
cipients, confirming prior, but not concurrent antibiotic ther-
apy as doubling the risk of primary progression to
immunotherapy and leading to a > 20-months shortening in
patients’ survival independent of established prognostic fac-
tors and corticosteroid use [10]. Whilst mirroring pre-clinical
evidence, where antibiotic pre-conditioning ahead of tumour
implantation leads to impaired responses to ICPI in mice
[26, 27], the expanding body of clinical studies has so far
painted an incomplete picture as to the mechanistic founda-
tions underlying the relationship between ATB and im-
munotherapy, a point of greater consequence given the
potential practice-influencing implications of ATB prescrib-
ing in the clinic.
Most of the studies highlighting the importance of a
healthy gut microbial environment as a pre-requisite for
ICPI response were unfortunately characterised by insuf-
ficient data on preceding or concomitant antibiotic ex-
posure, making it impossible to disentangle the role of
antibiotic-induced perturbation of the gut ecosystem in
influencing clinically meaningful outcomes in these pa-
tients [3].
Mechanistically, the breadth and depth of downstream
effects produced by antibiotics within the cancer-immune
synapse are an important challenge in studying this prog-
nostically adverse relationship. On one hand, the direct
bacteriostatic/bactericidal effect of antibiotics can cause
selective pressure within the host microbial ecosystem and
instigate an alternative microbiota state characterised,
amongst other traits, by downregulation of major histo-
compatibility complex (MHC) class I/II genes and im-
paired effector T-cell responses, immunologic traits
implicated in reduced responsiveness to ICPI [28].
ATB-induced depletion of gut bacteria can also shift
the repertoire of microbial-associated molecular patterns
(MAMPS). These molecules signal through mucosal in-
nate immune cells primarily via toll-like receptors
(TLRs) and NOD1 [29] to influence neutrophil priming,
reduce local cytokine release and prime adaptive
immunity by influencing the expression of MHC genes
within the intestinal mucosa and reduce immunoglobu-
lin secretion [30]. Antibiotic treatment impairs TH1/
TH17 responses in tumour-bearing mice through direct
pre-conditioning of the gut microbiota, reducing the effi-
cacy of cyclophosphamide-mediate immune-rejection of
the tumour [31]. In addition, antibiotics can also reduce
the capacity of adoptively transferred CD8+ T-cells to
mediate a tumour-specific response through altered
LPS/TLR4 signaling in lymphodepleted mice [32].
By disrupting the gut ecosystem, antibiotics instigate
downstream metabolic alterations within the microenviron-
ment with complex repercussions to the tumour-host-
microbe interface. Amongst them, changes in the availability
of short-chain fatty acids produced by Akkermansia, Faecali-
bacteria and Enterococcus from the catabolism of non-
digestible carbohydrates and the conversion of primary bile
acids to secondary bile acids (including deoxycholate) medi-
ated by Clostridiales can significantly alter gut homeostasis
and lead to profound and clinically meaningful immune-
modulatory consequences [33]. The immune-metabolic re-
percussions secondary to gut dysbiosis, potentially reversible
by oral Akkermansia supplementation [34], might explain
the influence of body mass index in determining response to
ICPI [35, 36].
With improved characterization of immune-microbiologic
underpinning of the relationship between antibiotics and
ICPI outcome, a key question now is whether disruption of a
well-equilibrated gut bacterial ecosystem is truly causal in
this relationship, and thus whether reversal of antibiotic-
mediated gut dysbiosis might prove beneficial in restoring
full sensitivity to ICPI. Whether a favourable gut microbiota
is a reflection of an otherwise healthy host rather than the
primum movens of clinically meaningful anti-cancer immune
responses is still the subject of intense debate [13]. To this
end, appreciating how antibiotics might dynamically affect
such a strong immune-microbiologic correlate of response to
checkpoint inhibition is of key importance to pave the way
for strategies that could restore or protect the integrity of this
important phenotypic correlate of response. To address the
multiplicity of mechanisms that are likely to underscore this
complex and bi-directional relationship, the coordinated
study of a number of fundamental pathophysiologic pro-
cesses including bacterial translocation, immune-modulation,
an altered metabolome, enzymatic degradation and reduced
diversity of the gut microbiome has been proposed as an
overarching framework [37].
Gaining sufficient insight as to the mode of action by
which bacteria might work as biotherapeutic agents is not
just important for patient prognostication, but is in fact key
to a successful, rational development of microbiome-
modulating therapies which improve patient’s outcome with
ICPI. With antibiotic use now having been validated as an
important and dynamic factor influencing outcome from
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immunotherapy, concerted efforts should be aimed at char-
acterizing the candidate taxonomic features in the gut micro-
biota that are associated with worse outcome from ICPI in
the context of preceding and concomitant antibiotic expos-
ure and evaluate them in conjunction with the concomitant
prescription of proton pump inhibitors, corticosteroids and
vaccines, all of which have been postulated to influence ICPI
response [38].
Recognising these changes is expected to facilitate the clin-
ical development of diverse biotherapeutic approaches to
induce microbiome reprogramming including dietary inter-
ventions with pre-biotics, therapeutic administration of single
or multiple types of bacterial species or their metabolites, se-
lective antibiotic therapy or faecal microbial transplantation,
all of which are currently at the focus of intense clinical re-
search efforts [26].
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